These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 9353406)
21. Analysis of the CD23-αv integrin interaction: a study with model peptides. Edkins AL; Borland G; Kelly SM; Cogdell RJ; Ozanne BW; Cushley W Biochem Biophys Res Commun; 2012 Jun; 422(2):207-12. PubMed ID: 22560905 [TBL] [Abstract][Full Text] [Related]
22. Studies on alpha v beta 3/ligand interactions using a [3H]SK&F-107260 binding assay. Wong A; Hwang SM; McDevitt P; McNulty D; Stadel JM; Johanson K Mol Pharmacol; 1996 Sep; 50(3):529-37. PubMed ID: 8794891 [TBL] [Abstract][Full Text] [Related]
23. Significance of RGD loop and C-terminal domain of echistatin for recognition of alphaIIb beta3 and alpha(v) beta3 integrins and expression of ligand-induced binding site. Marcinkiewicz C; Vijay-Kumar S; McLane MA; Niewiarowski S Blood; 1997 Aug; 90(4):1565-75. PubMed ID: 9269775 [TBL] [Abstract][Full Text] [Related]
24. Identification of a contact domain between echistatin and the integrin alpha(v)beta(3) by photoaffinity cross-linking. Scheibler L; Mierke DF; Bitan G; Rosenblatt M; Chorev M Biochemistry; 2001 Dec; 40(50):15117-26. PubMed ID: 11735394 [TBL] [Abstract][Full Text] [Related]
25. Pro-apoptotic signaling pathway activated by echistatin in GD25 cells. Alimenti E; Tafuri S; Scibelli A; D'Angelo D; Manna L; Pavone LM; Belisario MA; Staiano N Biochim Biophys Acta; 2004 Jul; 1693(1):73-80. PubMed ID: 15276326 [TBL] [Abstract][Full Text] [Related]
26. Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells. Duan X; Jia SF; Zhou Z; Langley RR; Bolontrade MF; Kleinerman ES Clin Exp Metastasis; 2004; 21(8):747-53. PubMed ID: 16035619 [TBL] [Abstract][Full Text] [Related]
27. Transmembrane-truncated alphavbeta3 integrin retains high affinity for ligand binding: evidence for an 'inside-out' suppressor? Mehta RJ; Diefenbach B; Brown A; Cullen E; Jonczyk A; Güssow D; Luckenbach GA; Goodman SL Biochem J; 1998 Mar; 330 ( Pt 2)(Pt 2):861-9. PubMed ID: 9480902 [TBL] [Abstract][Full Text] [Related]
28. Importance of the structure of the RGD-containing loop in the disintegrins echistatin and eristostatin for recognition of alpha IIb beta 3 and alpha v beta 3 integrins. McLane MA; Vijay-Kumar S; Marcinkiewicz C; Calvete JJ; Niewiarowski S FEBS Lett; 1996 Aug; 391(1-2):139-43. PubMed ID: 8706902 [TBL] [Abstract][Full Text] [Related]
29. Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. Del Gatto A; Zaccaro L; Grieco P; Novellino E; Zannetti A; Del Vecchio S; Iommelli F; Salvatore M; Pedone C; Saviano M J Med Chem; 2006 Jun; 49(11):3416-20. PubMed ID: 16722662 [TBL] [Abstract][Full Text] [Related]
30. Structure-activity studies of the s-echistatin inhibition of bone resorption. Sato M; Garsky V; Majeska RJ; Einhorn TA; Murray J; Tashjian AH; Gould RJ J Bone Miner Res; 1994 Sep; 9(9):1441-9. PubMed ID: 7817829 [TBL] [Abstract][Full Text] [Related]
31. Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinity. Kimura RH; Levin AM; Cochran FV; Cochran JR Proteins; 2009 Nov; 77(2):359-69. PubMed ID: 19452550 [TBL] [Abstract][Full Text] [Related]
32. Human alphavbeta3 integrin potency and specificity of TA138 and its DOTA conjugated form (89)Y-TA138. Mousa SA; Mohamed S J Cardiovasc Pharmacol; 2005 Feb; 45(2):109-13. PubMed ID: 15654258 [TBL] [Abstract][Full Text] [Related]
33. An echistatin C-terminal peptide activates GPIIbIIIa binding to fibrinogen, fibronectin, vitronectin and collagen type I and type IV. Wright PS; Saudek V; Owen TJ; Harbeson SL; Bitonti AJ Biochem J; 1993 Jul; 293 ( Pt 1)(Pt 1):263-7. PubMed ID: 7687129 [TBL] [Abstract][Full Text] [Related]
34. Superactivation of integrin alphavbeta3 by low antagonist concentrations. Legler DF; Wiedle G; Ross FP; Imhof BA J Cell Sci; 2001 Apr; 114(Pt 8):1545-53. PubMed ID: 11282030 [TBL] [Abstract][Full Text] [Related]
35. Sodium dodecyl sulfate-stable complexes of echistatin and RGD-dependent integrins: a novel approach to study integrins. Thibault G Mol Pharmacol; 2000 Nov; 58(5):1137-45. PubMed ID: 11040063 [TBL] [Abstract][Full Text] [Related]
37. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Mitjans F; Meyer T; Fittschen C; Goodman S; Jonczyk A; Marshall JF; Reyes G; Piulats J Int J Cancer; 2000 Sep; 87(5):716-23. PubMed ID: 10925366 [TBL] [Abstract][Full Text] [Related]
38. Differences in binding of (99m)Tc-disintegrins to integrin alphavbeta3 on tumor and vascular cells. Knight LC; Romano JE; Cosenza SC; Iqbal NM; Marcinkiewicz C Nucl Med Biol; 2007 May; 34(4):371-81. PubMed ID: 17499726 [TBL] [Abstract][Full Text] [Related]
39. Modulation of integrin antagonist signaling by ligand binding of the heparin-binding domain of vitronectin to the alphaVbeta3 integrin. Maile LA; Aday AW; Busby WH; Sanghani R; Veluvolu U; Clemmons DR J Cell Biochem; 2008 Oct; 105(2):437-46. PubMed ID: 18615592 [TBL] [Abstract][Full Text] [Related]
40. RGDX Yamada Y; Onda T; Hagiuda A; Kan R; Matsunuma M; Hamada K; Kikkawa Y; Nomizu M FASEB J; 2022 Jul; 36(7):e22389. PubMed ID: 35657599 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]